Education
About Us
Working with TipRanks
Follow Us
Arcellx, Inc. (ACLX)
:ACLX
ACLX Stock Chart & Stats
$89.98
-$3.36(-4.36%)
At close: 4:00 PM EST
$89.98
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $96.39
Previous CloseN/A
Volume227.93K
Average Volume (3M)507.73K
Market Cap
$5.20B
Enterprise Value$4.24B
Total Cash (Recent Filing)$461.38M
Total Debt (Recent Filing)$51.79M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Feb 26, 2026EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding57,822,872
10 Day Avg. Volume478,241
30 Day Avg. Volume507,732
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)9.03
Price to Sales (P/S)38.06
P/FCF Ratio-42.39
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue118.01
Enterprise Value/Gross Profit5.23K
Enterprise Value/Ebitda-20.22
Forecast
1Y Price Target
$114.73Price Target Upside27.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataUpdated iMMagine-1 data at ASH likely to further bolster anito-cel's safety and efficacy profile.
FDA ApprovalArcellx is preparing for a commercial launch of anito-cel in the US with expectations to supply the majority of 4L+ Multiple Myeloma patients without FDA-imposed quantity limits.
Safety ProfileThe durability of response and no signs of delayed neurotoxicities were shown with a median follow up of 12.6 months.
Bears Say
Financial PerformanceArcellx reported a net loss of $55.8 million for the quarter.
Market SentimentMacro factors are creating a stock overhang, which may affect investor sentiment despite the positive clinical data.
Arcellx Inc News
ACLX FAQ
What was Arcellx, Inc.’s price range in the past 12 months?
Arcellx, Inc. lowest stock price was $47.86 and its highest was $96.39 in the past 12 months.
What is Arcellx, Inc.’s market cap?
Arcellx, Inc.’s market cap is $5.20B.
When is Arcellx, Inc.’s upcoming earnings report date?
Arcellx, Inc.’s upcoming earnings report date is Feb 26, 2026 which is in 102 days.
How were Arcellx, Inc.’s earnings last quarter?
Arcellx, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.983 by -$0.007.
Is Arcellx, Inc. overvalued?
According to Wall Street analysts Arcellx, Inc.’s price is currently Undervalued.
Does Arcellx, Inc. pay dividends?
Arcellx, Inc. does not currently pay dividends.
What is Arcellx, Inc.’s EPS estimate?
Arcellx, Inc.’s EPS estimate is -0.97.
How many shares outstanding does Arcellx, Inc. have?
Arcellx, Inc. has 57,822,872 shares outstanding.
What happened to Arcellx, Inc.’s price movement after its last earnings report?
Arcellx, Inc. reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.983. Following the earnings report the stock price went up 0.788%.
Which hedge fund is a major shareholder of Arcellx, Inc.?
Currently, no hedge funds are holding shares in ACLX
Arcellx Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.73 (27.51% Upside)
$114.73 (27.51% Upside)
Blogger Sentiment
Neutral
ACLX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 216.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.36%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Company Description
Arcellx, Inc.
Arcellx Inc (ACLX) is a biotechnology company focused on developing innovative therapies for patients with cancer and other severe diseases. The company specializes in the development of its proprietary cell therapy platform, which leverages the unique properties of genetically engineered T cells to target and eliminate cancer cells. Arcellx is primarily engaged in the research, development, and commercialization of its lead product candidates, which are designed to address significant unmet medical needs in hematologic malignancies and other related conditions.
ACLX Stock 12 Month Forecast
Average Price Target
$114.73
▲(27.51% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.69% Insiders
26.67% Mutual Funds
21.72% Other Institutional Investors
36.05% Public Companies and
Individual Investors